Arrowhead Pharmaceuticals (ARWR) Competitors $15.31 -0.98 (-6.02%) Closing price 04:00 PM EasternExtended Trading$15.21 -0.10 (-0.65%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. BBIO, BPMC, ELAN, LEGN, TGTX, VRNA, TLX, AXSM, LNTH, and GRFSShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Axsome Therapeutics (AXSM), Lantheus (LNTH), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. BridgeBio Pharma Blueprint Medicines Elanco Animal Health Legend Biotech TG Therapeutics Verona Pharma Telix Pharmaceuticals Limited American Depositary Shares Axsome Therapeutics Lantheus Grifols BridgeBio Pharma (NASDAQ:BBIO) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Do institutionals & insiders believe in BBIO or ARWR? 99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend BBIO or ARWR? BridgeBio Pharma presently has a consensus target price of $57.09, suggesting a potential upside of 73.85%. Arrowhead Pharmaceuticals has a consensus target price of $42.13, suggesting a potential upside of 175.15%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Arrowhead Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is BBIO or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-241.44% N/A -75.69% Arrowhead Pharmaceuticals N/A -236.60%-64.09% Does the media refer more to BBIO or ARWR? In the previous week, Arrowhead Pharmaceuticals had 18 more articles in the media than BridgeBio Pharma. MarketBeat recorded 34 mentions for Arrowhead Pharmaceuticals and 16 mentions for BridgeBio Pharma. Arrowhead Pharmaceuticals' average media sentiment score of 0.83 beat BridgeBio Pharma's score of 0.80 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 10 Very Positive mention(s) 6 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, BBIO or ARWR? BridgeBio Pharma has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$127.42M48.94-$535.76M-$3.53-9.30Arrowhead Pharmaceuticals$545.21M3.88-$599.49M-$1.40-10.94 Does the MarketBeat Community believe in BBIO or ARWR? Arrowhead Pharmaceuticals received 372 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 72.47% of users gave BridgeBio Pharma an outperform vote while only 65.44% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBridgeBio PharmaOutperform Votes17972.47% Underperform Votes6827.53% Arrowhead PharmaceuticalsOutperform Votes55165.44% Underperform Votes29134.56% Which has more volatility & risk, BBIO or ARWR? BridgeBio Pharma has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. SummaryBridgeBio Pharma and Arrowhead Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.11B$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-2.968.9226.8419.71Price / Sales3.88253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book9.946.466.794.50Net Income-$599.49M$143.98M$3.23B$248.18M7 Day Performance2.68%3.04%4.07%1.14%1 Month Performance26.74%7.44%12.52%15.20%1 Year Performance-38.81%-2.46%16.83%6.56% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals3.5209 of 5 stars$15.31-6.0%$42.13+175.1%-34.4%$2.11B$545.21M-2.96400News CoveragePositive NewsAnalyst ForecastGap UpBBIOBridgeBio Pharma4.5948 of 5 stars$35.73+4.6%$57.09+59.8%+14.2%$6.78B$127.42M-12.52400Insider TradeBPMCBlueprint Medicines1.7929 of 5 stars$99.89+2.8%$126.56+26.7%-1.2%$6.46B$562.12M-92.63640Positive NewsInsider TradeELANElanco Animal Health3.2195 of 5 stars$12.78+6.8%$15.00+17.4%-23.1%$6.34B$4.43B31.949,800Analyst ForecastGap UpLEGNLegend Biotech3.5319 of 5 stars$32.63+2.7%$78.82+141.6%-33.8%$6.01B$627.24M-34.421,070News CoverageAnalyst RevisionGap UpTGTXTG Therapeutics3.8269 of 5 stars$34.97+4.0%$40.80+16.7%+115.2%$5.54B$386.39M-348.95290Positive NewsVRNAVerona Pharma2.6693 of 5 stars$68.03+7.4%$81.50+19.8%+484.7%$5.53B$118.54M-35.5330Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-5.6%$22.00+35.7%N/A$5.48B$783.21M0.00N/AGap DownAXSMAxsome Therapeutics4.7175 of 5 stars$110.41+2.5%$172.14+55.9%+39.7%$5.44B$432.16M-18.45380Positive NewsInsider TradeLNTHLantheus4.4469 of 5 stars$78.80-3.6%$132.67+68.4%-7.3%$5.39B$1.54B13.10700Positive NewsGRFSGrifols3.1975 of 5 stars$7.75+9.1%N/A+4.7%$5.35B$7.21B6.6526,300Positive News Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Verona Pharma Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Axsome Therapeutics Alternatives Lantheus Alternatives Grifols Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARWR Stock Free ARWR Stock Alerts